A HERON Webinar 6 October: “Including Commercially-Focused Endpoints in Clinical Trials: Process and Benefits”
REGISTER NOW - participation is complimentary but limited.
45 minute webinar program, 15 minute Q&A
Commercially-focused end points in clinical trials have become a practical reality, if not a necessity, with reform-driven global health policies and worsening economic conditions strong drivers in the alignment of product effectiveness with clinical efficacy. Given these market conditions, the evidence-based articulation of product value has never been as important.
Join HERON experts for an insightful perspective on the process and benefits of determining market access and other commercially determined endpoints in clinical trials. We’ll explore the value-add of doing so and the potential consequence of not, along with step-by-step review of the ‘what, where, when, and how’ of integrating these endpoints successfully in a clinical and regulatory focused process.
HERON’s webinar will be supported by real-life case studies and will include:
- Why HERON recommends the inclusion of commercially-focused endpoints
- HERON’s experienced approach to the identification, validation, and refinement of strategic commercial endpoints and options:
- The benefits of starting early and/or starting now, with a process guide on optimizing access at any point in the development lifecycle
- The derived value of commercial endpoints:
- Questions & Answers
It is HERON’s observation that our pharmaceutical and biotechnology clients are proactively –and in some cases consequently – realigning their thinking and approach to commercial endpoints, including them earlier in the development life cycle and strengthening their evidence base to support intuitive pricing, reimbursement and access strategies and strong stakeholder communications. REGISTER NOW